Method and related kit for detecting HER-2/CEP17 gene status based on rare cells

Abstract

The invention relates to a method and a related kit for detecting HER-2 / CEP17 gene status based on rare cells, wherein the method comprises the following steps: 1. acquiring a blood sample or a body fluid sample, wherein the sample includes a mixed cell population of circulating tumor cells or other rare cells and white blood cells; 2. diluting the sample by virtue of a buffer solution, removing plasma and recovering CTC or other rare cells; 3. cracking by virtue of a red blood cell lysis buffer, removing red blood cells and recovering CTC or other rare cells; 4. uniformly mixing and breeding magnetic particles coated with related anti-human leucocyte antigens and antibodies with the recovered cells, and combining so as to form a magnetic particle-white blood cell mixture; 5. isolating the magnetic particle-white blood cell mixture from other cells so as to obtain a mixed cell population containing CTC or other rare cells and a few of white blood cells; and 6. by virtue of a method combining immunofluorescence cytochemistry and fluorescence in-situ hybridization, determining the status of HER-2 / CEP17, and simultaneously identifying CTC or other rare cells.

Description

technical field [0001] The present invention relates to medical diagnostics, in particular to the detection of tumor cells. More specifically, the present invention relates to diagnostic methods for detecting cancer and evaluating treatment options for patients. Background technique [0002] Circulating tumor cells (Circulating Tumor Cell, CTC) refer to the tumor cells that enter the blood circulation, which can fall off into the blood from the primary tumor or metastases, and may also enter the blood before forming solid tumor lesions. Tumor cells invade the circulatory system, and most of them die within a short period of time due to the body’s immune recognition, mechanical killing, and self-apoptosis, and only a few survive and plant in distant or primary tissues and organs, and further develop into metastases. The most direct factor leading to tumor metastasis and recurrence. [0003] CTC is a "liquid biopsy" sample that can represent the primary tumor. Peripheral blo...

AI Technical Summary

Problems solved by technology

[0009] 1. As an invasive histological test limited by the location of the lesion, there are limitations such as difficulty or inability to obtain specimens, and repeated postoperative specimens cannot be obtained, resulting in the inability of tissue specimens to provide real-time monitoring information

[0010] 2. And affected by treatment, etc., the molecular information of tumor cells may change dynamically

For example, some studies have reported that patients with breast cancer who received neoadjuvant chemotherapy received biopsy before chemotherapy, and compared the results with postoperative pathology, and found that the expression of HER-2 was inconsistent before and after treatment.

[0011] 3. The existence of tumor tissue heterogeneity and the fact that single-point biopsy only reflects local information makes traditional histological detection lack of comprehensive and holistic evaluation, such as comprehensive evaluation of information on primary tumors and multiple metastases, etc.

Images